Impact of precision medicine in refractory malignancies

Bookmark and Share
Published: 6 Jun 2016
Views: 1146
Prof Maria Schwaederle - University of California, San Diego, USA

Prof Schwaederle speaks with ecancertv at ASCO 2016 about her meta-analysis of personalised therapy (selection based on biomarkers) in phase I studies.

Pooling data from 346 trials of personalised therapy versus those without, comprised of a total of 13,203 patients, her team found that personalised therapy correlated with improved response rate (RR) (30.6% vs 4.9%) as well as prolonged median progression free survival (PFS) (5.7 vs 2.95 months).

Analysis of trials arms utilising biomarker targeting (N = 234 arms) showed that a biomarker-based strategy statistically improved RR compared to targeted arms that lacked a biomarker-based approach (31.1% vs 5.1%), and further that a “genomic (DNA) biomarker” had higher RR than those using a “protein biomarker” (42% vs 22.4%).

Prof Schwaederle highlights the success of personalised therapy trials as potential for phase I trials to move beyond being a proof-of-concept, and recognised as therapeutically important for patients.